BN Business News
添加企业 →
本文翻译正在准备中。在此之前,我们暂时显示英文原文。

监管与法律 · 2021/9/271 分钟阅读

Prospective Grant of an Exclusive Patent License: Development of a Bispecific T Cell Engager for the Treatment and Cure of HIV-1

本地自动翻译 · 来源原始语言

摘要

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Gilead Sciences, Inc. ("Gilead") located in Foster City, CA.

来源原始语言: Federal Register — All Documents打开原始公告 →

探索专题

商业洞察 →